Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 8 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 3 |
| ENT Disorders Market - Introduction | 12 | 1 |
| GBI Research Report Guidance | 12 | 1 |
| ENT Disorders Market - Market Overview | 13 | 12 |
| Rising Global Population and Deteriorating Environmental Conditions Drive ENT Disorder Therapeutics | 13 | 1 |
| Gross Maldistribution | 13 | 1 |
| ENT Disorders Marked By Antibiotic Overuse | 13 | 1 |
| Entry of New Players Restricted by the Number of Generics and Stringent FDA Regulations | 14 | 1 |
| Ketolides - A New Class of Antibacterials | 14 | 1 |
| Revenue Forecasts | 15 | 1 |
| Annual Cost of Therapy | 16 | 1 |
| Treatment Usage Patterns | 17 | 2 |
| Diseased Population | 19 | 1 |
| Treatment Seeking Population | 20 | 1 |
| Diagnosed Population | 21 | 1 |
| Prescription Population | 22 | 1 |
| Drivers and Restraints of the ENT Disorders Market | 23 | 1 |
| ENT Disorders Market Drivers | 23 | 1 |
| Continuous Rise in the Disease Population | 23 | 1 |
| Increasing Prescriptions for Antibiotics | 23 | 1 |
| New Generation of Antibiotics Replacing the Older Antibiotics Due to Increase in Antibacterial Resistance for the Later | 24 | 1 |
| ENT Disorders Market Restraints | 24 | 1 |
| Tendency to Opt for Self Help or Alternative Therapies by the Patients Due to Self-Limiting Nature of the Disease | 24 | 1 |
| Weak Pipeline Dominated with Me-Too Drugs | 24 | 1 |
| Increasing Pressure on Physicians to Reduce Antibacterial Use | 24 | 1 |
| ENT Disorders Market - Therapeutic Landscape | 25 | 77 |
| Tonsillitis Market | 25 | 1 |
| Introduction | 25 | 1 |
| Revenue Forecasts | 26 | 1 |
| Branded and Generic Share | 27 | 1 |
| Annual Cost of Therapy | 28 | 1 |
| Treatment Flow Algorithm | 29 | 1 |
| Treatment Usage Patterns | 30 | 2 |
| Diseased Population | 32 | 1 |
| Treatment Seeking Population | 33 | 1 |
| Diagnosed Population | 34 | 1 |
| Prescription Population | 35 | 1 |
| Profiles of Key Drugs in the Tonsillitis Market | 36 | 1 |
| Zithromax | 36 | 1 |
| Levaquin | 36 | 1 |
| Ceftin | 37 | 1 |
| Geographical Segmentation | 38 | 2 |
| Sinusitis Market | 40 | 1 |
| Introduction | 40 | 1 |
| Increased Uptake of Nebulized Antibiotics | 41 | 1 |
| Minimally Invasive Endoscopic Sinus Surgery Effective in Chronic Sunusitis Patients | 41 | 1 |
| Revenue Forecasts | 41 | 2 |
| Branded and Generic Share | 43 | 1 |
| Annual Cost of Therapy | 44 | 1 |
| Treatment Flow Algorithm | 45 | 1 |
| Treatment Usage Patterns | 46 | 2 |
| Diseased Population | 48 | 1 |
| Treatment Seeking Population | 49 | 1 |
| Diagnosed Population | 50 | 1 |
| Prescription Population | 51 | 1 |
| Profiles of Key Drugs in the Sinusitis Market | 52 | 1 |
| Cipro XR | 52 | 1 |
| Clarithromycin | 52 | 1 |
| Augmentin | 52 | 1 |
| Geographical Segmentation | 53 | 2 |
| Rhinitis Market | 55 | 1 |
| Introduction | 55 | 1 |
| Current Treatment Options Cater to Most of the Market Needs | 55 | 1 |
| Revenue Forecasts | 56 | 1 |
| Branded and Generic Share | 57 | 1 |
| Annual Cost of Therapy | 58 | 1 |
| Treatment Flow Algorithm | 59 | 1 |
| Treatment Usage Patterns | 60 | 2 |
| Diseased Population | 62 | 1 |
| Treatment Seeking Population | 63 | 1 |
| Diagnosed Population | 64 | 1 |
| Prescription Population | 65 | 1 |
| Profiles of Key Drugs in the Rhinitis Market | 66 | 1 |
| Nasacort AQ (triamcinolone acetonide) | 66 | 1 |
| Astelin (azelastine hydrochloride) | 66 | 1 |
| Nasonex (mometasone furoate monohydrate) | 66 | 1 |
| Singulair (Montelukast Sodium) | 66 | 1 |
| Rhinocort Aqua (budesonide) | 66 | 1 |
| Veramyst (fluticasone furoate) | 66 | 1 |
| Xyzal (levocetirizine dihydrochloride) | 67 | 1 |
| Geographical Segmentation | 67 | 2 |
| Otitis Media Market | 69 | 1 |
| Introduction | 69 | 1 |
| Revenue Forecasts | 70 | 1 |
| Branded and Generic Share | 71 | 1 |
| Annual Cost of Therapy | 72 | 1 |
| Treatment Flow Algorithm | 73 | 1 |
| Treatment Usage Patterns | 74 | 1 |
| Diseased Population | 75 | 3 |
| Treatment Seeking Population | 78 | 1 |
| Diagnosed Population | 79 | 1 |
| Prescription Population | 79 | 2 |
| Profiles of Key Drugs in the Otitis Media Market | 81 | 1 |
| Cephalexin | 81 | 1 |
| Cefprozil | 81 | 1 |
| Ciprodex | 81 | 1 |
| Rocephin | 81 | 1 |
| Bactrim | 82 | 1 |
| Geographical Segmentation | 83 | 2 |
| Tracheobronchitis Market | 85 | 1 |
| Introduction | 85 | 1 |
| Revenue Forecasts | 86 | 1 |
| Branded and Generic Share | 87 | 1 |
| Annual Cost of Therapy | 88 | 2 |
| Treatment Flow Algorithm | 90 | 1 |
| Treatment Usage Patterns | 91 | 1 |
| Diseased Population | 92 | 1 |
| Treatment Seeking Population | 93 | 1 |
| Diagnosed Population | 94 | 1 |
| Prescription Population | 95 | 1 |
| Profiles of Key Drugs in the Tracheobronchitis Market | 96 | 1 |
| Augmentin Xr | 96 | 1 |
| Zithromax | 96 | 1 |
| Bactrim | 97 | 1 |
| Biaxin XI | 97 | 1 |
| Spectracef | 98 | 1 |
| Albuterol | 98 | 1 |
| Geographical Segmentation | 99 | 3 |
| ENT Disorders Market - Geographical Landscape | 102 | 26 |
| The US | 105 | 1 |
| Revenue Forecasts | 105 | 1 |
| Annual Cost of Therapy | 106 | 1 |
| Treatment Usage Patterns | 107 | 2 |
| Diseased Population | 109 | 1 |
| Treatment Seeking Population | 110 | 1 |
| Diagnosed Population | 111 | 1 |
| Prescription Population | 112 | 1 |
| Top Five Countries in Europe | 113 | 1 |
| Revenue Forecasts | 113 | 1 |
| Annual Cost of Therapy | 114 | 1 |
| Treatment Usage Patterns | 115 | 2 |
| Diseased Population | 117 | 1 |
| Treatment Seeking Population | 118 | 1 |
| Diagnosed Population | 119 | 1 |
| Prescription Population | 120 | 1 |
| Japan | 121 | 1 |
| Revenue Forecasts | 121 | 1 |
| Annual Cost of Therapy | 122 | 1 |
| Treatment Usage Patterns | 123 | 1 |
| Diseased Population | 124 | 1 |
| Treatment Seeking Population | 125 | 1 |
| Diagnosed Population | 126 | 1 |
| Prescription Population | 127 | 1 |
| ENT Disorders Market - Pipeline Analysis | 128 | 14 |
| Introduction | 128 | 2 |
| Research and Development Pipeline - Tonsillitis | 130 | 1 |
| Profiles of Molecules in Phase III | 130 | 1 |
| Research and Development Pipeline - Sinusitis | 131 | 1 |
| Phase III | 131 | 1 |
| Phase II | 132 | 1 |
| Phase I | 133 | 1 |
| Research and Development Pipeline - Rhinitis | 134 | 4 |
| Research and Development Pipeline - Otitis Media | 138 | 1 |
| Phase III | 139 | 2 |
| Phase II | 141 | 1 |
| Phase I | 141 | 1 |
| Preclinical | 141 | 1 |
| ENT Disorders Market - Competitive Landscape | 142 | 11 |
| Competitive Profiling | 142 | 1 |
| Abbott Laboratories | 142 | 1 |
| Company Overview | 142 | 1 |
| Product Profile | 142 | 1 |
| SWOT Profile | 142 | 1 |
| Bayer AG | 143 | 1 |
| Company Overview | 143 | 1 |
| Product Profile | 143 | 1 |
| SWOT Profile | 143 | 1 |
| GlaxoSmithKline | 144 | 1 |
| Company Overview | 144 | 1 |
| Product Profile | 144 | 1 |
| SWOT Profile | 145 | 1 |
| Johnson &Johnson (J&J) | 146 | 1 |
| Company Overview | 146 | 1 |
| Product Profile | 146 | 1 |
| SWOT Profile | 146 | 1 |
| Merck &Co | 147 | 1 |
| Company Overview | 147 | 1 |
| Product Profile | 147 | 1 |
| SWOT Profile | 147 | 1 |
| Pfizer | 148 | 1 |
| Company Overview | 148 | 1 |
| Product Profile | 148 | 1 |
| SWOT Profile | 148 | 1 |
| Novartis AG | 149 | 1 |
| Company Overview | 149 | 1 |
| SWOT Profile | 149 | 1 |
| Sandoz: Generic Division of Novartis | 149 | 1 |
| Product Profile | 150 | 1 |
| F. Hoffmann-La Roche Ltd. | 150 | 1 |
| Company Overview | 150 | 1 |
| Product Profile | 150 | 1 |
| SWOT Profile | 151 | 1 |
| Sanofi | 151 | 1 |
| Company Overview | 151 | 1 |
| Product Profile | 152 | 1 |
| SWOT Profile | 152 | 1 |
| ENT Disorders Market - Strategic Consolidations | 153 | 6 |
| Overview | 153 | 1 |
| ENT Disorders Market M&A Deals | 153 | 1 |
| M&A Deals by Geography | 154 | 1 |
| Deals by Type | 155 | 1 |
| Major M&A Deals | 156 | 1 |
| Shionogi to Acquire Rights of Nine Products from Victory Pharma - July 2011 | 156 | 1 |
| Merck Completes Acquisition of Inspire Pharmaceuticals - March 2011 | 156 | 1 |
| Ondine Biopharma Divested its Stake in Sinuwave Technologies - September 2010 | 156 | 1 |
| Victory Pharma Acquired MiddleBrook Pharmaceuticals in July 2010 | 156 | 1 |
| Pernix Acquired Rights for CEDAX from Shionogi Pharma in March 2010 | 156 | 1 |
| iNova Pharmaceuticals Entered Into Agreement With PH&T | 157 | 1 |
| R&D Licensing Agreements | 157 | 1 |
| Deals by Indication | 157 | 1 |
| Deals by Geography | 158 | 1 |
| MerLion Pharmaceuticals Enters Into Licensing Agreement with Alcon Pharmaceuticals for Finafloxacin | 158 | 1 |
| ENT Disorders Market - Appendix | 159 | 7 |
| Market Definitions | 159 | 1 |
| Abbreviations | 159 | 1 |
| Research Methodology | 160 | 5 |
| Coverage | 160 | 1 |
| Secondary Research | 160 | 1 |
| Primary Research | 161 | 1 |
| Therapeutic Landscape | 161 | 1 |
| Analogous Forecasting Methodology | 162 | 1 |
| Market Size by Geography | 162 | 1 |
| Forecasting Model for Therapeutic Areas | 163 | 1 |
| Geographical Landscape | 164 | 1 |
| Pipeline Analysis | 164 | 1 |
| Competitive Landscape | 164 | 1 |
| Expert Panel Validation | 164 | 1 |
| Contact Us | 164 | 1 |
| Disclaimer | 164 | 1 |
| Sources | 165 | 1 |